Bernd Fronhoff

Chief Operating Officer at N-Cardia SA

Bernd Fronhoff

Bernd Fronhoff

Chief Operating Officer at N-Cardia SA

Biography

Dr. Bernd Fronhoff is Chief Operating & Financial Officer at Axiogenesis AG.

Overview
Career Highlights

N-Cardia SA
Axiogenesis AG

RelSci Relationships

9

Number of Boards

1

Relationships
RelSci Relationships are individuals Bernd Fronhoff likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Scientific Officer at N-Cardia SA

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at N-Cardia SA

Relationship likelihood: Strong

Chief Executive Officer at N-Cardia SA

Relationship likelihood: Strong

Chief Executive Officer at V+ Management GmbH

Relationship likelihood: Average

Member, Scientific Advisory Board at Axiogenesis AG

Relationship likelihood: Average

Member, Scientific Advisory Board at Axiogenesis AG

Relationship likelihood: Average

Former Chief Executive Officer, Portfolio Management at Duerckheim GmbH

Relationship likelihood: Average

Former Vice Chairman, Advisory Board at Axiogenesis AG

Relationship likelihood: Average

Former Member, Advisory Board at Axiogenesis AG

Relationship likelihood: Average

Paths to Bernd Fronhoff
Potential Connections via
Relationship Science
You
Bernd Fronhoff
Chief Operating Officer at N-Cardia SA
Career History
Chief Operating Officer
2017 - Current

N-Cardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Plymouth Meeting, PA.

Chief Operating & Financial Officer
2001 - Prior

Axiogenesis AG engages in the development and commercialization of in vitro models of healthy and diseased cell types and tissue. Its flagship offering is the Cor.4U human cardiomyocyte product, derived from induced pluripotent stem cells, which is used in applications for single cell analysis to high-throughput screening of pharmaceutical compounds. The firm’s products include Murine Cardiomyocytes, Murine Endothelial Cells and Murine Smooth Muscle Cells. Its services include electrophysiology services, toxicology and customized services. The firm operates through its offices located in Cologne and Plymouth Meeting. The company was founded by Heribert Bohlen in November 2010 and is headquartered in Cologne, Germany.

Boards & Committees
Member, Executive Board
Current

Ncardia AG engages in the development and commercialization of vitro models of healthy and diseased cell types and tissue. The firm's products include Murine Cardiomyocytes, Murine Endothelial Cells and Murine Smooth Muscle Cells. Its services include electrophysiology services, toxicology and customized services. The company was founded on November 7, 2000 by Heribert Bohlen and is headquartered in Cologne, Germany.

Other Affiliations

Bernd Fronhoff is affiliated with N-Cardia SA, Axiogenesis AG, Axiogenesis AG

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bernd Fronhoff. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bernd Fronhoff's profile does not indicate a business or promotional relationship of any kind between RelSci and Bernd Fronhoff.